Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

@article{Ray2017InclisiranIP,
  title={Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol},
  author={K. Ray and U. Landmesser and Lawrence A Leiter and D. Kallend and R. Dufour and M. Karakas and T. Hall and Roland P T Troquay and T. Turner and F. Visseren and P. Wijngaard and R. Wright and J. Kastelein},
  journal={The New England Journal of Medicine},
  year={2017},
  volume={376},
  pages={1430–1440}
}
BACKGROUND In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low‐density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers. METHODS We conducted a phase 2, multicenter, double‐blind, placebo‐controlled, multiple‐ascending‐dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for… Expand
389 Citations

Paper Mentions

Interventional Clinical Trial
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for… Expand
ConditionsAtherosclerotic Cardiovascular Disease, Diabetes, Familial Hypercholesterolemia
InterventionDrug
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
  • 3
Inclisiran-New hope in the management of lipid disorders?
  • 10
Evolocumab and clinical outcomes in patients with cardiovascular disease.
  • 3
  • PDF
Inclisiran for the treatment of dyslipidemia
  • 15
Inclisiran, the billion-dollar drug, to lower LDL cholesterol – is it worth it?
  • S. Doggrell
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2020
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
  • 1,526
  • PDF
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  • 2,277
  • PDF
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
  • 760
  • PDF
...
1
2
3
...